Provided by Tiger Fintech (Singapore) Pte. Ltd.

Royalty Pharma plc

31.11
-0.6800-2.14%
Post-market: 31.110.00000.00%17:19 EDT
Volume:7.26M
Turnover:224.91M
Market Cap:13.47B
PE:16.27
High:31.70
Open:31.30
Low:30.45
Close:31.79
Loading ...

Company Profile

Company Name:
Royalty Pharma plc
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
- -
Office Location:
110 East 59th Street,New York,New York,United States
Zip Code:
10022
Fax:
- -
Introduction:
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Directors

Name
Position
Christopher Hite
Executive Vice President,Vice Chairman
Pablo Legorreta
Chairman and Chief Executive Officer
Henry Fernandez
Lead Independent Director
M. Germano Giuliani
Non-Management Director
Rory Riggs
Non-Management Director
Bonnie Bassler
Director
Catherine Engelbert
Director
David Hodgson
Director
Errol De Souza
Director
Greg Norden
Director
Ted Love
Director

Shareholders

Name
Position
Pablo Legorreta
Chairman and Chief Executive Officer
Terrance Coyne
Executive Vice President,Chief Financial Officer
George Lloyd
Executive Vice President, Investments & General Counsel
James Reddoch
Executive Vice President,Chief Scientific Officer
Marshall Urist
Executive Vice President, Research & Investments